Amicapsil’s effect on pressure injuries in SCI
Read more
Read more
Both studies find 100% closure rates
for acute and chronic pressure injuries
are on NHS Supply Chain
quicker than antibiotics and antiseptics.
Effective on resistant infections and does not contribute to AMR.
Effective on resistant infections and does not contribute to AMR.
Effective on resistant infections and does not contribute to AMR.
Review article discussing
the wound microbiome and Amicapsil
Review article discussing
the wound microbiome and Amicapsil
Review article discussing
the wound microbiome and Amicapsil
acting via the skin and wound microbiome without the use of antimicrobials.
acting via the skin and wound microbiome without the use of antimicrobials.
acting via the skin and wound microbiome without the use of antimicrobials.
Effective wound treatment in immunocompetent and immunocompromised persons.
Effective wound treatment in immunocompetent and immunocompromised persons.
Effective on antibiotic and antiseptic resistant wound infections.
Effective in immunocompetent and immunocompromised persons.
The Microbiome Supporting Soap is ideal for sensitive skin, including the skin of babies and toddlers.
The Microbiome Supporting Soap is ideal for sensitive skin, including the skin of babies and toddlers.
The Microbiome Supporting Soap is ideal for sensitive skin, including the skin of babies and toddlers.
“From 4 weeks of absolute hell – to being pain-free, getting a full night’s sleep and back to normal at work.”
“From 4 weeks of absolute hell, in pain 24 hours a day, struggling at work – to being pain-free, getting a full night’s sleep and back to normal at work.”
“From 4 weeks of absolute hell, in pain 24 hours a day, struggling at work – to being pain-free, getting a full night’s sleep and back to normal at work.”
NH ( patient)
NH ( patient)
NH ( patient)
Effective in treating severe infections, including infections not responding to antibiotics and antiseptics.
Effective in treating severe infections, including infections not responding to antibiotics and antiseptics.
Effective in treating severe infections, including infections not responding to antibiotics and antiseptics.
60% quicker removal of infection than antibiotics and antisepics.
60% quicker removal of infection than antibiotics and antisepics.
60% quicker removal of infection than antibiotics and antisepics.
No additives or chemicals
No additives or chemicals
No additives or chemicals
Infection causes pain and by removing the infection, Amicapsil and SertaSil reduce the pain.
Infection causes pain and by removing the infection, Amicapsil and SertaSil reduce the pain.
Infection causes pain and by removing the infection, Amicapsil and SertaSil reduce the pain.
Effective treatment of wounds and pressure ulcers in SCI-persons and in controlling soft tissue infection caused by osteomyelitis.
Effective treatment of wounds and pressure ulcers in SCI-persons and in controlling soft tissue infection caused by osteomyelitis.
Effective treatment of wounds and pressure ulcers in SCI-persons and in controlling soft tissue infection caused by osteomyelitis.
climate change
VH (patient)
VH (patient)
VH (patient)
it is biologically recyclable and does not require the use of chemicals, plastics or antimicrobials.
Research & Development
As a healthcare company, Willingsford focuses on the healing of complicated wounds. Experience has repeatedly shown that what sounds ingenious as a theory on the drawing board or looks very promising in the artificially controlled environment of the laboratory does not always turn out to perform as remarkably as hoped for once transferred into the real life environment. Underlying diseases as well as non-artificially created situations and injuries heavily affect the outcome of the recovery processes. Therefore, in Willingsford, we focus on what works in patients in real life.
We do all our research in accordance with the principles of the pharmaceutical industry and, of course, our development is done to the highest standards of the industry. We only settle for products that show substantial benefits to patients.
We know what we do best and focus on that. Consequently, we are only interested in truly novel solutions or therapies that provide real therapeutical improvements. For the same reasons, we do not pursue the development of follow-on products nor do we try to create an artificial need.
This approach may not help us grow into the biggest commercial healthcare company in the world. We believe, however, that keeping this focus, will allow us to retain a high degree of overall company agility and quick decision making which, again, will allow us to create the right environment for doing what we are good at, namely Challenge dogmas, Interpret & trust data, Innovate and Create change.